Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BLU-5937

Phase 3Small molecule

1

Indications

8

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Cough

NCT05600777

Clinical

Trials by Indication[1]

Chronic Cough2 trials

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Completed·—·Phase 2·NCT04678206·310 enrolled

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

Terminated·—·Phase 2·NCT03979638·68 enrolled

Tics2 trials

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

Completed·—·Phase 1·NCT05570539·30 enrolled

BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

Completed·—·Phase 1·NCT03638180·90 enrolled

Cough2 trials

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)

Completed·BBellus Health Inc. - a GSK company·Phase 3·NCT05599191·957 enrolled

A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)

Active, not recruiting·BBellus Health Inc. - a GSK company·Phase 3·NCT05600777·997 enrolled

Adult1 trial

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

Completed·—·Phase 1·NCT06179537·34 enrolled

Atopic Dermatitis1 trial

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

Completed·—·Phase 2·NCT04693195·142 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for BLU-5937. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BLU-5937 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BLU-5937. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Related News